… Board. Dr. Dryja will play a key strategic role in the development and advancement of ProQR’s growing ophthalmology pipeline. LEIDEN, The Netherlands, Nov. 09, …
… pigmentosa (adRP) due to the P23H mutation in the rhodopsin ( RHO ) gene. ODD provides a special status for … ) gene. The trial will include a single-dose escalation (open label) arm and a multiple-dose (double-masked) arm in … of visual function and retinal structure through ophthalmic endpoints such as visual acuity (BCVA), visual …
… pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene. P23H is the most prevalent mutation … gene. The trial will include a single-dose escalation (open label) arm and a multiple-dose (double-masked) arm in … of visual function and retinal structure through ophthalmic endpoints such as visual acuity (BCVA), visual …
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th
… ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an … PQ-010-001, is expected to be completed in June 2017. Topline safety and exploratory efficacy data from the … QR-010 is designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma GmbH). eFlow® is a …